Recommended ART for High-Risk HIV-Exposed Newborn

Risk Stratification and Rationale

For newborns whose mothers received no antiretroviral therapy before or during labor, the recommended regimen is single-dose nevirapine 2 mg/kg oral suspension immediately after birth PLUS zidovudine for 6 weeks, as per the guidelines from Praxis Medical Insights 1
No maternal ART during pregnancy, only intrapartum zidovudine, is a high-risk feature for perinatal HIV transmission, according to Praxis Medical Insights 1
Premature delivery at 35 weeks with birthweight 1.8 kg is a high-risk feature for perinatal HIV transmission, as stated by Praxis Medical Insights 1

Single-dose nevirapine combined with zidovudine has demonstrated superior efficacy compared to single-dose nevirapine alone when mothers have not received antiretroviral drugs, as reported by Praxis Medical Insights 1
Nevirapine achieves therapeutic concentrations rapidly, with prolonged elimination in neonates, supporting single-dose prophylaxis, according to Praxis Medical Insights 1

Administer nevirapine 2 mg/kg oral suspension immediately after birth or within 72 hours, as recommended by Praxis Medical Insights 1
Giving the dose as soon as possible after birth is critical for effectiveness, as stated by Praxis Medical Insights 1
The complete regimen for this newborn should include nevirapine: 2 mg/kg single dose at birth, as per Praxis Medical Insights 1
The complete regimen for this newborn should include zidovudine: 4 mg/kg twice daily for 6 weeks, as recommended by Praxis Medical Insights 1

Lopinavir/ritonavir is an alternative agent but not preferred for neonates in this scenario, as it can be used in infants aged ≥4 weeks to 2 years as an alternative regimen, according to MMWR Recommendations and Reports 2
Darunavir/ritonavir requires the infant to be ≥3 years old and ≥10 kg for safety and dosing, making it inappropriate for this 1.8 kg premature newborn, as stated by MMWR Recommendations and Reports 2
Raltegravir is listed as an alternative for infants ≥2 kg, but nevirapine remains the preferred third agent based on the extensive evidence base for prevention of mother-to-child transmission, as reported by MMWR Recommendations and Reports 2

No serious adverse events related to nevirapine were observed in multiple studies, as reported by Praxis Medical Insights 1

Immediate administration after birth maximizes effectiveness, as stated by Praxis Medical Insights 1
Follow-up HIV testing should be performed to confirm the infant's HIV status, as recommended by Praxis Medical Insights 1